In the United States, doctors often prescribe low doses of aspirin every day for people between 50 and 70 years of age to prevent heart attacks and strokes (ACV), even if they have never had a related disease.
In Europe, cardiologists do this only after the first heart problem.
Aspirin Blood fluid and prevent the formation of clots in the arteries. But too smooth blood can cause bleeding. Therefore it's a dilemma: for what kind of patients are the benefits of reducing cardiovascular risk greater than the risk of bleeding?
For people who have had a stroke or heart attack, the balance is clearly leaning towards taking aspirin, according to many studies. These people have a clear risk of a second accident, and aspirin helps prevent it.
A new study, published on Tuesday at Journal of the American Medical Association (Jama), offer broader vision for patients who do not have cardiovascular problems.
But that really doesn't resolve controversy: it states that, on the one hand, aspirin reduces the risk of heart attack and stroke in people who have no history; but, on the other hand, it increases the risk of severe bleeding, especially in the brain, stomach and intestines.
Aspirin does not affect death in one way or another.
"For healthy people, the low benefit of aspirin to prevent strokes and heart attacks is equivalent to the increased risk of bleeding," said Jane Armitage, professor of epidemiology at the University of Oxford.
In conclusion, then, doctors should recommend aspirin on a case by case basisdepending on other risks of the patient, write cardiologist Michael Gaziano in a comment.
For example, stopping smoking or lowering cholesterol levels is another method to try to reduce cardiovascular risk.
This new study is a meta-analysis, which means that the two authors, from King & # 39; s College London, studied 13 of the most important clinical trials on subjects from 1988 to 2018 and drew conclusions based on all of these tests.
This method makes it possible to remove the uncertainties associated with each study and to identify general effects in general, based on 164,000 people who participated in the trial in total.
What was surprising was the researcher they found no association between aspirin and a reduction in the number of cancer cases, contrary to what more and more research has shown that aspirin reduces the risk of certain cancers, especially colorectal cancer.
In such a way that the United States Preventive Services Working Group (US Task Force on Prevention Services), a body that issues public health recommendations, supports since 2016 for daily intake of aspirin in people from 50 to 69 years to, among other things, reduce this cancer incidence.
With information from AFP